Potassium channel modulators

A compound having formula (I-a):

• or a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or stereoisomer, wherein
• each T is independently Ga, alkyl, halogen, haloalkyl, oxo, —CN, —NO2, —ORa, —NRaRb, —SRa, —S(O)Ra, —S(O)2Ra, —C(O)Ra, —C(O)ORa, —C(O)NRaRb, —(CRzaRzb)m—CN, —(CRzaRzb)m—NO2, —(CRzaRzb)m—ORa, —(CRzaRzb)m—NRaRb, —(CRzaRzb)m—S(O)Ra, —(CRzaRzb)m—S(O)2Ra, —(CRzaRzb)m—C(O)Ra, —(CRzaRzb)m—C(O)ORa, —(CRzaRzb)m—C(O)NRaRb, or —(CRzaRzb)m-Ga;
• q is 0, 1, 2, 3, or 4;
• X is C(O);
• R1 is G1a or —(CR1aR1b)n-G1a;
• R2 is alkyl;
• G1a is polycyclic cycloalkyl which is unsubstituted or substituted with 1, 2, 3, or 4 substituents independently selected from the group consisting of Ga, alkyl, halogen, haloalkyl, oxo, —CN, —NO2, —ORa, —NRaRb, —SRa, —S(O)Ra, —S(O)2Ra, —C(O)Ra, —C(O)ORa, —C(O)NRaRb, —(CRzaRzb)m—CN, —(CRzaRzb)m—NO2, —(CRzaRzb)m—ORa, —(CRzaRzb)m—NRaRb, —(CRzaRzb)m—SRa, —(CRzaRzb)m—S(O)2Ra, —(CRzaRzb)m—C(O)Ra, and —(CRzaRzb)m—C(O)NRaRb;
• Ga, at each occurrence, is independently aryl or C3—C6 cycloalkyl;
• each of which is independently unsubstituted or substituted with 1, 2, or 3 substituents selected from the group consisting of alkyl, halogen, haloalkyl, oxo, —CN, —NO2, —ORa, —NRaRb, —SRa, —S(O)Ra, —S(O)2Ra, —C(O)Ra, —C(O)ORa, —C(O)NRaRb, —(CRzaRzb)m—CN, —(CRzaRzb)m—NO2, —(CRzaRzb)m—ORa, —(CRzaRzb)m—NRaRb, —(CRzaRzb)m—SRa, —(CRzaRzb)m—S(O)Ra, —(CRzaRzb)m—S(O)2Ra, —(CRzaRzb)m—C(O)Ra, —(CRzaRzb)m—C(O)ORa, and —(CRzaRzb)m—C(O)NRaRb;
• Ra and Rb, at each occurrence, are each independently hydrogen, alkyl, or haloalkyl;
• R1a and R1b, at each occurrence, are each independently hydrogen, alkyl, halogen, or haloalkyl;
• Rzaand Rzb, at each occurrence, are each independently hydrogen, alkyl, halogen, or haloalkyl;
• and
• m and n, at each occurrence, are each independently 1, 2, 3, or 4.